ResearcherJuntendo UniversityActive in the last 2 years
Ko Tomishima
Matched on ORCID iD 0000-0003-2487-3837; OpenAlex author ID A5037731741. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 6
- Evaluation of tumor detection capability for pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm in each MRI sequence. First author DOI 10.4103/sjg.sjg_91_26↗
- Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000002411↗
- Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Based Chemotherapy. Co-author DOI 10.1097/mpa.0000000000002151↗
- Effect of Mirogabalin on Chemotherapy-induced Peripheral Neuropathy Caused by Gemcitabine Plus Nab-paclitaxel Therapy in Pancreatic Cancer Patients: A Pilot St… Co-author DOI 10.21203/rs.3.rs-948459/v2↗
- IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer. Co-author DOI 10.3390/diagnostics11071140↗
- Successful Management of Hemosuccus Pancreaticus due to Pancreatic Adenocarcinoma by Chemoradiotherapy. Co-author DOI 10.2169/internalmedicine.4372-19↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hiroyuki Isayama · 6 shared papers, 2020–2026 · strength 0.91
- Paper Evaluation of tumor detection capability for pancreatic ductal adenocarcinoma concomitant with intraductal papillary mu… DOI 10.4103/sjg.sjg_91_26↗
- Paper Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclita… DOI 10.1097/mpa.0000000000002411↗
- Paper Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Bas… DOI 10.1097/mpa.0000000000002151↗
- Toshio Fujisawa · 5 shared papers, 2020–2026 · strength 0.71
- Paper Evaluation of tumor detection capability for pancreatic ductal adenocarcinoma concomitant with intraductal papillary mu… DOI 10.4103/sjg.sjg_91_26↗
- Paper Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Bas… DOI 10.1097/mpa.0000000000002151↗
- Paper Effect of Mirogabalin on Chemotherapy-induced Peripheral Neuropathy Caused by Gemcitabine Plus Nab-paclitaxel Therapy i… DOI 10.21203/rs.3.rs-948459/v2↗
- Yusuke Takasaki · 4 shared papers, 2021–2026 · strength 0.61
- Paper Evaluation of tumor detection capability for pancreatic ductal adenocarcinoma concomitant with intraductal papillary mu… DOI 10.4103/sjg.sjg_91_26↗
- Paper Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Bas… DOI 10.1097/mpa.0000000000002151↗
- Paper Effect of Mirogabalin on Chemotherapy-induced Peripheral Neuropathy Caused by Gemcitabine Plus Nab-paclitaxel Therapy i… DOI 10.21203/rs.3.rs-948459/v2↗
- Yasuhisa Jimbo · 1 shared paper, 2026 · strength 0.22
- Dai Mohri · 1 shared paper, 2025 · strength 0.20
- Takashi Sasaki · 1 shared paper, 2025 · strength 0.20
- Saburo Matsubara · 1 shared paper, 2025 · strength 0.20
- Tsuyoshi Takeda · 1 shared paper, 2025 · strength 0.20
- Kei Saito · 1 shared paper, 2025 · strength 0.20
- Hiroki Oyama · 1 shared paper, 2025 · strength 0.20
- Makoto Ueno · 1 shared paper, 2025 · strength 0.20
- Yousuke Nakai · 1 shared paper, 2025 · strength 0.20
- Mitsuhiro Fujishiro · 1 shared paper, 2025 · strength 0.20
- Raj K. Puri · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.